To the Editor: At the request of the editors, additional disclosure of potential conflicts of interest is provided, covering relationships that I did not discern to be pertinent to the scope of the letter1 that was published July 27, 2011. As previously reported, I served on an advisory board for Ameritox and co-chaired the American Pain Society–American Academy of Pain Medicine Opioid Guideline panel, for which I received reimbursement for travel expenses. In addition to these sources of financial remuneration, I have served on the advisory boards of Archimedes, Covidien, King (Pfizer), Meda, Purdue Pharma, Forest Laboratories, and Neuroadjuvants; provided medical legal consulting for Cephalon and Janssen; participated in CME activities for King (Pfizer), Endo, Pricara, and OrthoMcNeil; and served on speakers' bureaus for Pricara and OrthoMcNeil. I have received funds for research and writing assistance from Cephalon. I am the president of the American Academy of Pain Medicine, a board member of the American Pain Foundation (a nonprofit foundation that receives support from manufacturers of prescription opioids), and chair of the National Initiative on Pain Control through the American Pain Foundation. Additionally, I am a strategic consultant for Capital Caring in Washington, DC, and I have served as an expert witness for Cephalon, have received grants from the National Institutes of Health and book royalties from The Hospice Companion, and have a 5% ownership in Asante medical education company. Additional board positions have been held with the Ossipee Lake Alliance. I regret that the disclosures were not reported with the original letter. A correction and related letter appear in this issue of JAMA, and the original letter to the editor has been corrected online.